Translating complex science into novel medicines in the clinic

Rare disease and oncology clinical trials

At Recursion, we are redefining the drug discovery and development process to bring life-changing treatments to patients faster. Recursion clinical trials are designed to address significant unmet medical needs, focusing on conditions where new options are needed most, evaluating the differentiated potential medicines developed using insights from the Recursion OS. We are committed to transparency, patient safety, and clinical excellence as we work to transform the future of medicine through every study we conduct.

Expanded Access Policy
Expanded Access Policy

At Recursion Pharmaceuticals, we are committed to radically improving the lives of patients and their families by developing therapies that will make a lasting, positive, and transformative impact on diseases and conditions for which there are high unmet needs.

We believe that the best way to succeed in our mission is through well-designed clinical trials that determine the safety and effectiveness of investigational medicines. We understand that in some rare and specific circumstances, when enrollment into a clinical trial is not possible, physicians caring for patients with serious or life-threatening conditions or diseases may seek special access to investigational medicines. When appropriate and through an expanded access protocol, Recursion will consider individual Expanded Access, sometimes called “Compassionate Use” or “Early Access”, requests for an investigational medicine outside of an ongoing clinical trial for the indication being investigated by the company.

There may be additional requirements, but to start, a licensed treating physician must submit the request for Expanded Access in writing by contacting ExpandedAccess@Recursion.com. The physician must be able and willing to obtain a treatment IND, or regional equivalent, and Institutional Review Board or Ethics Committee approval, for the patient prior to initiating treatment with our investigational medicine.

We will consider applications to provide the investigational drug that will not, among other things, compromise the scientific validity of our broader development programs, or interfere with or delay clinical trials or regulatory filings designed to make the drug available to a larger patient population.

We endeavor to respond to Expanded Access requests within one week after the steps for submission are completed.

It is important to remember that investigational medicinal products have not yet received regulatory approval; thus, their potential risks and benefits are not yet established. Physicians and patients should consider all possible benefits and risks when seeking access to an investigational medicinal product. For information on available clinical trials visit: www.ClinicalTrials.gov.

Clinical Trial Transparency
Clinical Trial Transparency

Recursion is committed to maintaining the highest level of integrity and ethics across all clinical trials and investigational programs, including the timely and transparent disclosure of clinical trial information and results.

All company-sponsored Phase 2 and 3 clinical trials are posted on country-specific registries of clinical trials, such as clinicaltrials.gov. As part of our commitment to advancing science in the therapeutic areas in which we work, Recursion discloses results of these trials on public registries within 12 months following the trial completion date. To keep our patients informed, clinical trial results will be made available to participants in that trial upon request. Additionally, Recursion aims to submit an abstract of the primary analysis of clinical trial results for publication regardless of trial outcome or regulatory approval status.

TUPELO clinical trial for patients living with familial adenomatous polyposis (FAP)

The TUPELO trial is a Phase 1b/2 clinical trial for individuals diagnosed with familial adenomatous polyposis. The trial is evaluating the impact of an investigational drug called REC-4881 on clinical efficacy and safety for those living with FAP. The trial is open-label, meaning that the research team and you know that you are receiving a study drug, all eligible participants taking part in the trial will receive REC-4881.

Learn more about the TUPELO trial

ELUCIDATE clinical trial for patients with advanced solid tumors

The ELUCIDATE trial is a Phase 1/2 clinical trial for individuals with advanced solid tumors, with a current focus on ovarian cancer. The trial is evaluating the impact of an investigational drug called REC-617, alone and in combination with appropriate standard of care agents, on clinical efficacy and safety for those living with cancer. The trial is open-label, meaning that the research team and you know that you are receiving a study drug, all eligible participants taking part in the trial will receive REC-617.

Learn more about the ELUCIDATE trial

DAHLIA clinical trial for patients with biomarker-enriched solid tumors and lymphoma

The DAHLIA trial is a Phase 1/2 clinical trial for individuals with biomarker-enriched solid tumors and lymphoma. The trial is evaluating the impact of an investigational drug called REC-1245 on clinical efficacy and safety for those living with cancer. The trial is open-label, meaning that the research team and you know that you are receiving a study drug, all eligible participants taking part in the trial will receive REC-1245.

Learn more about the DAHLIA trial

EXCELERIZE clinical trial for patients with B-cell malignancies

The EXCELERIZE trial is a Phase 1 clinical trial for individuals with B-cell malignancies including chronic lymphocytic leukemia (CLL). The trial is evaluating the impact of an investigational drug called REC-3565 on clinical efficacy and safety for those living with cancer. The trial is open-label, meaning that the research team and you know that you are receiving a study drug, all eligible participants taking part in the trial will receive REC-3565.

Learn more about the EXCELERIZE trial
© 2025 Recursion. All rights reserved.